Berthier A M, Pommereuil M, Scarabin P Y, Conard J
Thromb Haemost. 1985 Jun 24;53(3):433-6.
For laboratory control of oral anticoagulation, amidolytic factor X (F X) determination may offer an alternative to standardization difficulties of prothrombin time (PT). In order to validate this amidolytic assay on a large scale, a multicenter study was undertaken in 6 French laboratories using the same chromogenic substrate (Stachrom X Stago) and different automated instruments. Intra and between laboratory reproducibility of factor X was estimated on fresh and lyophilized patients plasmas and was found to be highly satisfactory. Standardization of the method did not seem to depend on the chromogenic substrate used, as investigated in two different centers. Results of PT and factor X were compared in over 500 patients on a long-term stabilized oral anticoagulant treatment: there was a strong positive correlation between the 2 tests in each center. The therapeutic range for factor X was evaluated from therapeutic PT values reported by Duckert and Marbet for the different thromboplastin reagents: the estimated mean range was 21 to 32%. Pooling the results of the six different centers a concordant information for prothrombin time and factor X amidolytic assay was found in 76% of patients and a fully discordant response was present in 0.6%. The results suggest that amidolytic factor X may be suitable for monitoring long-term anticoagulation. However, prospective trials are needed to evaluate its usefulness as compared to conventional methods.
对于口服抗凝治疗的实验室监测,测定酰胺水解性因子X(FX)可能是解决凝血酶原时间(PT)标准化难题的一种替代方法。为了大规模验证这种酰胺水解测定法,在6家法国实验室开展了一项多中心研究,这些实验室使用相同的显色底物(Stachrom X Stago)和不同的自动化仪器。在新鲜和冻干的患者血浆上评估了因子X在实验室内和实验室间的可重复性,结果发现非常令人满意。正如在两个不同中心所研究的那样,该方法的标准化似乎并不取决于所使用的显色底物。对500多名接受长期稳定口服抗凝治疗的患者的PT和因子X结果进行了比较:每个中心的这两项检测之间存在很强的正相关性。根据Duckert和Marbet报告的不同凝血活酶试剂的治疗性PT值评估了因子X的治疗范围:估计的平均范围为21%至32%。汇总六个不同中心的结果,发现76%的患者凝血酶原时间和因子X酰胺水解测定结果一致,0.6%的患者反应完全不一致。结果表明,酰胺水解性因子X可能适用于长期抗凝监测。然而,需要进行前瞻性试验来评估其与传统方法相比的实用性。